Atopic dermatitis is a chronic dermatological condition characterized by skin dryness and itching. This condition progresses over time and is not contagious through contact.
The main drug classes used to treat atopic dermatitis include corticosteroids, emollients/moisturizers, IL-4 and PDE4 inhibitors, calcineurin inhibitors, antibiotics, and others. Corticosteroids are anti-inflammatory drugs that mimic cortisol and are employed in the treatment of various diseases, including rheumatological conditions, rheumatoid arthritis, lupus, and atopic dermatitis. These drugs can be administered through various modes, such as topical, injectable, and oral, and are available through different distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The atopic dermatitis market research report is one of a series of new reports from The Business Research Company that provides atopic dermatitis market statistics, including atopic dermatitis industry global market size, regional shares, competitors with an atopic dermatitis market share, detailed atopic dermatitis market segments, market trends and opportunities, and any further data you may need to thrive in the atopic dermatitis industry. This atopic dermatitis market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The atopic dermatitis market size has grown rapidly in recent years. It will grow from $8.61 billion in 2024 to $9.88 billion in 2025 at a compound annual growth rate (CAGR) of 14.7%. The growth in the historic period can be attributed to medical understanding and awareness, incidence and prevalence rates, patient advocacy and support, treatment options evolution, research and development.
The atopic dermatitis market size is expected to see rapid growth in the next few years. It will grow to $17.08 billion in 2029 at a compound annual growth rate (CAGR) of 14.7%. The growth in the forecast period can be attributed to biologic therapies advancements, immunomodulators and small molecule drugs, pediatric-specific treatments, gene therapy and precision medicine, digital health integration. Major trends in the forecast period include technological advancements in topicals, pediatric ad care focus, environmental and allergen management, precision diagnosis tools.
The forecast of 14.7% growth over the next five years reflects a modest reduction of 0.4% from the previous estimate for this market. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. dermatology care by inflating prices of biologic treatments and therapeutic moisturizers developed in Denmark and France, resulting in prolonged flare-ups and higher specialty pharmacy expenditures. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The rising prevalence of atopic dermatitis is expected to drive significant growth in the atopic dermatitis market. Also known as eczema, atopic dermatitis is a skin condition characterized by dryness and itchiness. As the number of individuals affected by this condition increases, so does the demand for effective diagnosis and treatment options. For example, according to Oxford Academic, a UK-based publishing company, atopic dermatitis is highly prevalent worldwide, impacting around 2.6% of the global population, which translates to approximately 204 million people in 2024. This population includes about 101 million adults and 103 million children. Consequently, the growing incidence of atopic dermatitis is fueling the expansion of the atopic dermatitis market.
The growing demand for personalized medicine is anticipated to contribute significantly to the expansion of the atopic dermatitis market. Personalized medicine involves tailoring medical interventions, including drug therapies, to suit individual patient characteristics, such as genetics and molecular factors. This approach ensures more targeted and effective treatments while minimizing adverse effects. For example, as of October 2022, reports indicated a vast array of over 75,000 genetic testing products and 300 personalized medicines, underlining the surging demand for tailored therapeutic options. This trend is fueling the growth of the atopic dermatitis market by emphasizing more precise and patient-centric treatment approaches.
Innovations in product development are emerging as a pivotal trend within the atopic dermatitis market, with major companies introducing novel solutions to reinforce their market position. Notably, in June 2022, Regeneron Pharmaceuticals Inc., a prominent US-based biotechnology company, secured FDA approval for Dupixent (dupilumab). Dupixent is a medication designed for children aged 6 months to 5 years with moderate-to-severe atopic dermatitis. This groundbreaking drug works by inhibiting the signaling of two critical Type 2 inflammatory sources (IL-4 and IL-13), contributing to the development of various conditions such as eosinophilic esophagitis, prurigo nodularis, chronic rhinosinusitis with nasal polyposis, and asthma. The approval of Dupixent represents a significant advancement in pediatric atopic dermatitis treatment, promising more effective therapeutic options for young patients.
Major companies within the atopic dermatitis market are strategically pursuing product approvals to stimulate revenue growth within their industry. Product approvals signify the official endorsement granted by health regulatory bodies, affirming the safety and effectiveness of pharmaceuticals or treatments for managing inflammatory skin conditions like atopic dermatitis. Notably, in January 2022, AbbVie Inc., a prominent US-based pharmaceutical company, secured FDA approval for Rinvoq. Rinvoq, containing upadacitinib as its active component, belongs to the class of janus kinase (JAK) inhibitors, a targeted synthetic disease-modifying antirheumatic drug. This medication received approval for treating moderate-to-severe atopic dermatitis in both adults and children aged 12 years and above. Rinvoq serves as an alternative when other treatments, including biologic medicines or conventional medications, have been ineffective in managing the condition, or when their usage is not recommended. It is noteworthy that Rinvoq (upadacitinib) can be administered in conjunction with methotrexate or as monotherapy, thereby broadening treatment options for atopic dermatitis patients.
In September 2022, Arcutis Biotherapeutics, a prominent commercial-stage biopharmaceuticals firm headquartered in the United States, finalized the acquisition of Ducentis BioTherapeutics for an undisclosed sum. This strategic acquisition is envisioned to reinforce Arcutis Biotherapeutics' position within the medical dermatology sector while enhancing its capacity to address the unmet medical needs of patients dealing with dermatological conditions. Notably, Ducentis BioTherapeutics, a preclinical-stage biotechnology company also based in the US, specializes in the development of primary treatments targeting atopic dermatitis, aligning with Arcutis Biotherapeutics' commitment to advancing therapies for this skin disorder.
Major companies operating in the atopic dermatitis market are Sanofi SA, Meda AB, Regeneron Pharmaceuticals Inc., Novartis International AG, Pfizer Inc., AbbVie Inc., Astellas Pharma Inc., Arcutis Biotherapeutics Inc., Asana Biosciences LLC, Dermavant Sciences Inc., Eli Lilly and Company, Galderma SA, Incyte Corporation, Bayer AG, Bausch Health Companies Inc., Boehringer Ingelheim International GmbH, GlaxoSmithKline PLC, F Hoffmann-La Roche AG, LEO Pharma A/S, Teva Pharmaceutical Industries Ltd., Mylan MV, Allergan PLC, Encore Dermatology Inc., Menlo Therapeutics Inc., Johnson & Johnson, Merck & Co Inc., Roche Holding AG, Valeant Pharmaceuticals International Inc., Amgen Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Eisai Co. Ltd., Gilead Sciences Inc., Ipsen Biopharmaceuticals Inc., Kyowa Kirin Co. Ltd., Mallinckrodt Pharmaceuticals Limited
North America was the largest region in the atopic dermatitis market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the atopic dermatitis market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the atopic dermatitis market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The atopic dermatitis market consists of sales of biologics, CNI immunosuppressant drugs, and skin barrier emollients. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Atopic Dermatitis Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on atopic dermatitis market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for atopic dermatitis ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The atopic dermatitis market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Drug Class: Corticosteroids; Emollients Or Moisturizers; IL-4 And PDE4 Inhibitors; Calcineurin Inhibitors; Antibiotics; Other Drug Classes
- 2) By Mode of Administration: Topical; Injectable; Oral
- 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
- Subsegments:
- 1) By Corticosteroids: Topical Corticosteroids; Systemic Corticosteroids
- 2) By Emollients Or Moisturizers: Creams and Lotions; Ointments and Balms; Barrier Repair Creams
- 3) By IL-4 And PDE4 Inhibitors: Dupilumab (IL-4 Inhibitor); Apremilast (PDE4 Inhibitor)
- 4) By Calcineurin Inhibitors: Tacrolimus Ointment; Pimecrolimus Cream
- 5) By Antibiotics: Topical Antibiotics; Systemic Antibiotics
- 6) By Other Drug Classes: Antihistamines; Biologics; JAK Inhibitors
- Companies Mentioned: Sanofi SA; Meda AB; Regeneron Pharmaceuticals Inc.; Novartis International AG; Pfizer Inc.; AbbVie Inc.; Astellas Pharma Inc.; Arcutis Biotherapeutics Inc.; Asana Biosciences LLC; Dermavant Sciences Inc.; Eli Lilly and Company; Galderma SA; Incyte Corporation; Bayer AG; Bausch Health Companies Inc.; Boehringer Ingelheim International GmbH; GlaxoSmithKline PLC; F Hoffmann-La Roche AG; LEO Pharma A/S; Teva Pharmaceutical Industries Ltd.; Mylan MV; Allergan PLC; Encore Dermatology Inc.; Menlo Therapeutics Inc.; Johnson & Johnson; Merck & Co Inc.; Roche Holding AG; Valeant Pharmaceuticals International Inc.; Amgen Inc.; AstraZeneca PLC; Bristol-Myers Squibb Company; Eisai Co. Ltd.; Gilead Sciences Inc.; Ipsen Biopharmaceuticals Inc.; Kyowa Kirin Co. Ltd.; Mallinckrodt Pharmaceuticals Limited
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Atopic Dermatitis Market Characteristics
3. Atopic Dermatitis Market Trends And Strategies
4. Atopic Dermatitis Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Atopic Dermatitis Growth Analysis And Strategic Analysis Framework
- 5.1. Global Atopic Dermatitis PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Atopic Dermatitis Market Growth Rate Analysis
- 5.4. Global Atopic Dermatitis Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Atopic Dermatitis Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Atopic Dermatitis Total Addressable Market (TAM)
6. Atopic Dermatitis Market Segmentation
- 6.1. Global Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Corticosteroids
- Emollients/Moisturizers
- IL-4 and PDE4 Inhibitors
- Calcineurin Inhibitors
- Antibiotics
- Other Drug Classes
- 6.2. Global Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Topical
- Injectable
- Oral
- 6.3. Global Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- 6.4. Global Atopic Dermatitis Market, Sub-Segmentation Of Corticosteroids, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Topical Corticosteroids
- Systemic Corticosteroids
- 6.5. Global Atopic Dermatitis Market, Sub-Segmentation Of Emollients Or Moisturizers, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Creams and Lotions
- Ointments and Balms
- Barrier Repair Creams
- 6.6. Global Atopic Dermatitis Market, Sub-Segmentation Of IL-4 And PDE4 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Dupilumab (IL-4 Inhibitor)
- Apremilast (PDE4 Inhibitor)
- 6.7. Global Atopic Dermatitis Market, Sub-Segmentation Of Calcineurin Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Tacrolimus Ointment
- Pimecrolimus Cream
- 6.8. Global Atopic Dermatitis Market, Sub-Segmentation Of Antibiotics, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Topical Antibiotics
- Systemic Antibiotics
- 6.9. Global Atopic Dermatitis Market, Sub-Segmentation Of Other Drug Classes, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antihistamines
- Biologics
- JAK Inhibitors
7. Atopic Dermatitis Market Regional And Country Analysis
- 7.1. Global Atopic Dermatitis Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Atopic Dermatitis Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Atopic Dermatitis Market
- 8.1. Asia-Pacific Atopic Dermatitis Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Atopic Dermatitis Market
- 9.1. China Atopic Dermatitis Market Overview
- 9.2. China Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Atopic Dermatitis Market
- 10.1. India Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Atopic Dermatitis Market
- 11.1. Japan Atopic Dermatitis Market Overview
- 11.2. Japan Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Atopic Dermatitis Market
- 12.1. Australia Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Atopic Dermatitis Market
- 13.1. Indonesia Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Atopic Dermatitis Market
- 14.1. South Korea Atopic Dermatitis Market Overview
- 14.2. South Korea Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Atopic Dermatitis Market
- 15.1. Western Europe Atopic Dermatitis Market Overview
- 15.2. Western Europe Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Atopic Dermatitis Market
- 16.1. UK Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Atopic Dermatitis Market
- 17.1. Germany Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Atopic Dermatitis Market
- 18.1. France Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Atopic Dermatitis Market
- 19.1. Italy Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Atopic Dermatitis Market
- 20.1. Spain Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Atopic Dermatitis Market
- 21.1. Eastern Europe Atopic Dermatitis Market Overview
- 21.2. Eastern Europe Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Atopic Dermatitis Market
- 22.1. Russia Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Atopic Dermatitis Market
- 23.1. North America Atopic Dermatitis Market Overview
- 23.2. North America Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Atopic Dermatitis Market
- 24.1. USA Atopic Dermatitis Market Overview
- 24.2. USA Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Atopic Dermatitis Market
- 25.1. Canada Atopic Dermatitis Market Overview
- 25.2. Canada Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Atopic Dermatitis Market
- 26.1. South America Atopic Dermatitis Market Overview
- 26.2. South America Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Atopic Dermatitis Market
- 27.1. Brazil Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Atopic Dermatitis Market
- 28.1. Middle East Atopic Dermatitis Market Overview
- 28.2. Middle East Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Atopic Dermatitis Market
- 29.1. Africa Atopic Dermatitis Market Overview
- 29.2. Africa Atopic Dermatitis Market, Segmentation By Drug Class, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Atopic Dermatitis Market, Segmentation By Mode of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Atopic Dermatitis Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Atopic Dermatitis Market Competitive Landscape And Company Profiles
- 30.1. Atopic Dermatitis Market Competitive Landscape
- 30.2. Atopic Dermatitis Market Company Profiles
- 30.2.1. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Meda AB Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Regeneron Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. Novartis International AG Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Atopic Dermatitis Market Other Major And Innovative Companies
- 31.1. AbbVie Inc.
- 31.2. Astellas Pharma Inc.
- 31.3. Arcutis Biotherapeutics Inc.
- 31.4. Asana Biosciences LLC
- 31.5. Dermavant Sciences Inc.
- 31.6. Eli Lilly and Company
- 31.7. Galderma SA
- 31.8. Incyte Corporation
- 31.9. Bayer AG
- 31.10. Bausch Health Companies Inc.
- 31.11. Boehringer Ingelheim International GmbH
- 31.12. GlaxoSmithKline PLC
- 31.13. F Hoffmann-La Roche AG
- 31.14. LEO Pharma A/S
- 31.15. Teva Pharmaceutical Industries Ltd.
32. Global Atopic Dermatitis Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Atopic Dermatitis Market
34. Recent Developments In The Atopic Dermatitis Market
35. Atopic Dermatitis Market High Potential Countries, Segments and Strategies
- 35.1 Atopic Dermatitis Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Atopic Dermatitis Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Atopic Dermatitis Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
